Phase 2 Results for Nano-formulated NSAIDs under Development at Iroko Pharmaceuticals to Be Reported at American College of Rheumatology Meeting  
11/4/2011 7:38:54 AM

PHILADELPHIA--(BUSINESS WIRE)--The results of the Phase 2 program sponsored by Iroko Pharmaceuticals to develop novel, lower-dose formulations of a widely used class of pain medicines will be reported November 7th at the annual meeting of the American College of Rheumatology (ACR) in Chicago.